PDF(Pubmed)
Abstract：
UNASSIGNED: The administration of chemotherapy positively correlates with diverse adverse drug reactions, including the significant impact of hematological hazards such as anemia, leukopenia-neutropenia, thrombocytopenia, and pancytopenia. This pilot pharmacoeconomic study aimed to estimate the total direct costs of treating hematological toxicity induced by chemotherapy and its main determinants.
UNASSIGNED: The study was conducted as a retrospective cost of illness study using the \"from bottom to the top\" approach from the perspective of the Republic Health Insurance Fund. This study included 88 patients treated due to developing at least one episode of one of the types of hematological complications of cytostatics in 2018 at the Oncology Clinic of the University Clinical Center Kragujevac, Kragujevac, the Republic of Serbia.
UNASSIGNED: Among cancer patients who developed haematological toxicity, treating pancytopenia was most demanding in a pharmacoeconomic manner compared to neutropenia and thrombocytopenia, with an estimated value of direct costs of 264,14, 178,19 and 157,76 euros per patient per year respectively. Regarding total direct costs, the main determinants were the costs of drugs, their parenteral administration, and costs due to hospitalization.
UNASSIGNED: Due to the rising cancer incidence and obligatory hospital treatment of hematological toxicity induced by chemotherapy, the identification of the pharmacoeconomic aspects of the treatment of these complications is needed. Future research should focus on the development of new modalities of treatment regarding patient characteristics anticipating high costs.
UNASSIGNED: The study was conducted as a retrospective cost of illness study using the \"from bottom to the top\" approach from the perspective of the Republic Health Insurance Fund. This study included 88 patients treated due to developing at least one episode of one of the types of hematological complications of cytostatics in 2018 at the Oncology Clinic of the University Clinical Center Kragujevac, Kragujevac, the Republic of Serbia.
UNASSIGNED: Among cancer patients who developed haematological toxicity, treating pancytopenia was most demanding in a pharmacoeconomic manner compared to neutropenia and thrombocytopenia, with an estimated value of direct costs of 264,14, 178,19 and 157,76 euros per patient per year respectively. Regarding total direct costs, the main determinants were the costs of drugs, their parenteral administration, and costs due to hospitalization.
UNASSIGNED: Due to the rising cancer incidence and obligatory hospital treatment of hematological toxicity induced by chemotherapy, the identification of the pharmacoeconomic aspects of the treatment of these complications is needed. Future research should focus on the development of new modalities of treatment regarding patient characteristics anticipating high costs.
摘要：
未经批准：化疗与多种药物不良反应呈正相关，包括贫血等血液学危害的重大影响，白细胞减少-中性粒细胞减少症,血小板减少症,和全血细胞减少症.这项初步的药物经济学研究旨在评估治疗化疗引起的血液学毒性的总直接费用及其主要决定因素。
UNASSIGNED：从共和国健康保险基金的角度，使用“从下到上”的方法进行了疾病回顾性成本研究。这项研究包括88名患者，他们在2018年在大学临床中心Kragujevac的肿瘤学诊所中至少发生了一种细胞抑制剂的血液学并发症。克拉古耶瓦茨,塞尔维亚共和国。
未经证实：在出现血液毒性的癌症患者中，与中性粒细胞减少症和血小板减少症相比，治疗全血细胞减少症是最苛刻的，每位患者每年的直接费用估计值分别为264,14,178,19和157,76欧元。关于直接总成本，主要决定因素是药物成本，他们的肠胃外给药，以及住院费用。
UASSIGNED：由于癌症发病率的上升和化疗引起的血液学毒性的强制住院治疗，需要确定这些并发症治疗的药物经济学方面.未来的研究应集中在针对预期高成本的患者特征的新治疗方式的开发上。
UNASSIGNED：从共和国健康保险基金的角度，使用“从下到上”的方法进行了疾病回顾性成本研究。这项研究包括88名患者，他们在2018年在大学临床中心Kragujevac的肿瘤学诊所中至少发生了一种细胞抑制剂的血液学并发症。克拉古耶瓦茨,塞尔维亚共和国。
未经证实：在出现血液毒性的癌症患者中，与中性粒细胞减少症和血小板减少症相比，治疗全血细胞减少症是最苛刻的，每位患者每年的直接费用估计值分别为264,14,178,19和157,76欧元。关于直接总成本，主要决定因素是药物成本，他们的肠胃外给药，以及住院费用。
UASSIGNED：由于癌症发病率的上升和化疗引起的血液学毒性的强制住院治疗，需要确定这些并发症治疗的药物经济学方面.未来的研究应集中在针对预期高成本的患者特征的新治疗方式的开发上。
